Trials / Withdrawn
WithdrawnNCT02772575
A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)
A PILOT STUDY TO IDENTIFY MOLECULAR PREDICTORS OF SENSITIVITY AND RESISTANCE TO TRANS-ARTERIAL EMBOLIZATION OF PRIMARY LIVER TUMORS AND LIVER METASTASES
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if certain genes the tumor can help predict how the tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the hereditary material in humans. Identifying a gene that can predict how liver tumors will respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Hepatic trans-arterial embolization (TAE) | |
| DEVICE | MRI/CT scan | |
| PROCEDURE | biopsy | |
| OTHER | blood draw |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-01-01
- First posted
- 2016-05-13
- Last updated
- 2017-01-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02772575. Inclusion in this directory is not an endorsement.